Thursday, 21 October 2021 02:49 GMT

Senate Legal Committee endorses narcotics, psychotropic substances bill

(MENAFN- Jordan News Agency) Amman, Sept 6 (Petra) –– The Senate's Legal Committee on Monday approved the narcotics and psychotropic substances law as passed by the Lower House.
Senate President Faisal Fayez, who chaired the committee's session, called for working in partnership with all official and civil institutions to counter the threat of drugs and raise community awareness of their dangers through holding events and conferences to highlight their dangerous effects.
He stressed the role of civil society institutions in raising awareness, including the media, universities, schools, places of worship and youth clubs "to highlight the impact of this dangerous scourge on society and the future of our youth."
The Senate head commended the key and leading role of the Public Security Directorate and the Anti-Narcotics Department in combating drug trade, noting their awareness campaigns and treatment and rehabilitation efforts.
Fayez called for combatting and eradicating drug use through a comprehensive anti-crime strategy, noting the importance of the draft law, which stiffened the penalties but gave first-time offenders the opportunity to engage with society and start a new life.
Head of the Committee Ahmed Tbishat and Minister of State for Legal Affairs Mahmoud Kharabsheh told a press conference after the meeting that the draft legislation stiffened the penalty for first-time drug users, but without registering a security record against them in order to give them the chance to correct themselves and not to deprive them of the right to work, a stipulation in the previous law, while stiffening the penalty for addicts.


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.